clinical trial · NCT04201093
Fixed-Dose Trial in Early Parkinson's Disease (PD)
AbbVie·phase3·completed·n = 529
Parkinson DiseaseTavapadonPlaceboTavapadon
brief summary
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
started
Dec 13, 2019
primary completion
Jun 28, 2024
completion
Jun 28, 2024
last updated
Jul 28, 2025
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol